Results 101 to 110 of about 50,593 (147)

Coexistence of Hypertrophic Cardiomyopathy and Arterial Hypertension: Current Insights and Future Directions. [PDF]

Diseases
Katsi V, Papadomarkaki K, Manousiadis K, Triantafyllou E, Fragoulis C, Tsioufis K.   +5 more
europepmc   +1 more source

Impact of Mavacamten Approval on Septal Reduction Therapy Rates in Hypertrophic Cardiomyopathy. [PDF]

J Am Heart Assoc
Ibrahim R, Wang W, Pham HN, Abdelnabi M, Lester SJ, Wilansky S, Schaff HV, Geske JB, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

Still at sea: a patient's ongoing journey with non-obstructive hypertrophic cardiomyopathy. [PDF]

Eur Heart J Case Rep
Goldie FC, Myles RC, Coats CJ.
europepmc   +1 more source

GAK antagonises ROCK-dependent regulation of actomyosin dynamics. [PDF]

J Cell Sci
Hiramoto M, Takano N, Kokuba H, Kazama H, Hino H, Handa H, Miyazawa K.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

In vitro and in vivo effects of inhibitors on actin and myosin

Bioorganic and Medicinal Chemistry, 2021
The interaction of actin and myosin is essential for cell migration. We have identified kaempferol and pentahalogenated pseudilins as efficient inhibitors of migration of MDA-MB-231 breast adenocarcinoma cells. The compounds were studied with respect to possible effects on myosin-2-ATPase activity.
Sabine Richter, Hans-Joachim Knölker
exaly   +3 more sources

Myosin Inhibitors

Journal of the American College of Cardiology, 2023
Ajith Nair, Lola Xie, Jorge E. Silva Enciso   +2 more
exaly   +2 more sources

Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management

Annals of Pharmacotherapy, 2023
Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A literature search was conducted on PubMed from origin to
Alyssa Sykuta, Connie H. Yoon, Sarah Baldwin, Natalie I. Rine, Michael Young, Adam Smith   +5 more
openaire   +2 more sources

Blebbistatin, a Myosin II Inhibitor, Is Photoinactivated by Blue Light

Biochemistry, 2004
Blebbistatin is a small molecule inhibitor discovered in a screen for inhibitors of nonmuscle myosin IIA. Blebbistatin inhibits the actin-activated MgATPase activity and in vitro motility of class II myosins. In cells, it has been shown to inhibit contraction of the cytokinetic ring.
Takeshi, Sakamoto, John, Limouze, Christian A, Combs, Aaron F, Straight, James R, Sellers   +4 more
openaire   +2 more sources

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel, Andy, Wang, Srihari S, Naidu, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources